TipRanks
Advertisement
Advertisement

DE:0IT Stock Latest News

Analyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress
RatingsAnalyst Reiterates Buy on Satellos Bioscience, Maintains Unchanged $22 Price Target Amid Steady DMD Trial Progress
16h ago
MSLE
Satellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular Dystrophy
PremiumCompany Announcements
Satellos Completes Enrollment in BASECAMP Phase 2 Trial of Forazapadin for Duchenne Muscular Dystrophy
1d ago
6K
MSLE
Satellos announces enrollment completed for BASECAMP
PremiumThe Fly
Satellos announces enrollment completed for BASECAMP
1d ago
MSLE
Satellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $22
PremiumRatings
Satellos Bioscience: Regulatory Advances and Upcoming DMD Readouts Support Buy Rating, Price Target Maintained at $22
7d ago
MSLE
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding
PremiumCompany Announcements
Satellos Wins FDA Green Light for FSHD Trial and Secures Up to US$5 Million in Non-Dilutive Funding
7d ago
MSLE
Satellos announces U.S. FDA cleared IND application for forazapadin
PremiumThe FlySatellos announces U.S. FDA cleared IND application for forazapadin
7d ago
MSLE
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress
Premium
Company Announcements
Satellos Bioscience to Showcase Forazapadin Program at World Muscle Society Congress
16d ago
6K
MSLE
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance
Premium
Company Announcements
Satellos Bioscience Secures INN ‘Forazapadin’ for Lead Duchenne Drug as Phase 2 Programs Advance
22d ago
6K
MSLE
Satellos assigns forazapadin name to SAT-3247
PremiumThe Fly
Satellos assigns forazapadin name to SAT-3247
22d ago
MSLE
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences
PremiumCompany Announcements
Satellos Bioscience to Showcase DMD Drug Program at September Investor Conferences
1M ago
6K
MSLE
Buy Rating on Satellos Bioscience Highlights Transformative Potential of First-in-Class Oral DMD Therapy Ahead of Key 4Q26 Phase 2 Readouts
PremiumRatings
Buy Rating on Satellos Bioscience Highlights Transformative Potential of First-in-Class Oral DMD Therapy Ahead of Key 4Q26 Phase 2 Readouts
1M ago
MSLE
Satellos initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Satellos initiated with an Outperform at LifeSci Capital
1M ago
MSLE
Satellos: Buy Rating Reiterated as Phase 2 Progress Advances and $18 Price Target Remains Unchanged
PremiumRatingsSatellos: Buy Rating Reiterated as Phase 2 Progress Advances and $18 Price Target Remains Unchanged
2M ago
MSLE
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility
Premium
Company Announcements
Satellos Bioscience Sets Up US$50 Million U.S. At-the-Market Share Sales Facility
2M ago
6K
MSLE
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base
Premium
Company Announcements
Satellos Bioscience Posts Larger Q2 2026 Loss on Higher R&D but Doubles Equity Base
2M ago
6K
MSLE
Satellos files $300M mixed securities shelf
PremiumThe Fly
Satellos files $300M mixed securities shelf
2M ago
MSLE
Satellos price target raised to $18 from $11 at H.C. Wainwright
PremiumThe Fly
Satellos price target raised to $18 from $11 at H.C. Wainwright
3M ago
MSLE
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients
PremiumCompany Announcements
Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients
3M ago
6K
MSLE
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247
PremiumCompany Announcements
Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247
3M ago
6K
MSLE
Satellos announces Fast Track designation for SAT-3247
PremiumThe FlySatellos announces Fast Track designation for SAT-3247
3M ago
MSLE
Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026
Premium
Company Announcements
Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026
3M ago
6K
MSLE
Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 Annual Meeting
Premium
Company Announcements
Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 Annual Meeting
4M ago
6K
MSLE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >